A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor

Raynier Devillier, Sabine Fürst, Roberto Crocchiolo, Jean El-Cheikh, Luca Castagna, Samia Harbi, Angela Granata, Evelyne D'Incan, Diane Coso, Christian Chabannon, Christophe Picard, Anne Etienne, Boris Calmels, Jean Marc Schiano, Claude Lemarie, Anne Marie Stoppa, Reda Bouabdallah, Norbert Vey, Didier Blaise

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N=74) or MMUD (N=40). We compared outcome of MUD versus MMUD patients. There was no difference in the cumulative incidence of grades II-IV acute GVHD (MUD: 34% vs. MMUD: 35%, P=0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5% vs. MMUD: 15%, P=0.016). The cumulative incidences of overall chronic GVHD (MUD: 33% vs. MMUD: 22%, P=0.088) and extensive chronic GVHD (MUD: 20% vs. MMUD: 19%, P=0.594) were comparable. One-year NRM was similar in both groups (MUD: 16% vs. MMUD: 14%, P=0.292); similarly, progression-free survival (MUD: 59% vs. MMUD: 55%, P=0.476) and overall survival (MUD: 63% vs. MMUD: 61%, P=0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47%) and 19 of 40 MMUD patients (48%) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients.

Original languageEnglish
Pages (from-to)83-87
Number of pages5
JournalAmerican Journal of Hematology
Volume89
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Busulfan
Unrelated Donors
Antilymphocyte Serum
Homologous Transplantation
Rabbits
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Incidence
fludarabine
Mortality
Hematologic Neoplasms
Immunosuppressive Agents
Disease-Free Survival

ASJC Scopus subject areas

  • Hematology

Cite this

A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. / Devillier, Raynier; Fürst, Sabine; Crocchiolo, Roberto; El-Cheikh, Jean; Castagna, Luca; Harbi, Samia; Granata, Angela; D'Incan, Evelyne; Coso, Diane; Chabannon, Christian; Picard, Christophe; Etienne, Anne; Calmels, Boris; Schiano, Jean Marc; Lemarie, Claude; Stoppa, Anne Marie; Bouabdallah, Reda; Vey, Norbert; Blaise, Didier.

In: American Journal of Hematology, Vol. 89, No. 1, 01.2014, p. 83-87.

Research output: Contribution to journalArticle

Devillier, R, Fürst, S, Crocchiolo, R, El-Cheikh, J, Castagna, L, Harbi, S, Granata, A, D'Incan, E, Coso, D, Chabannon, C, Picard, C, Etienne, A, Calmels, B, Schiano, JM, Lemarie, C, Stoppa, AM, Bouabdallah, R, Vey, N & Blaise, D 2014, 'A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor', American Journal of Hematology, vol. 89, no. 1, pp. 83-87. https://doi.org/10.1002/ajh.23592
Devillier, Raynier ; Fürst, Sabine ; Crocchiolo, Roberto ; El-Cheikh, Jean ; Castagna, Luca ; Harbi, Samia ; Granata, Angela ; D'Incan, Evelyne ; Coso, Diane ; Chabannon, Christian ; Picard, Christophe ; Etienne, Anne ; Calmels, Boris ; Schiano, Jean Marc ; Lemarie, Claude ; Stoppa, Anne Marie ; Bouabdallah, Reda ; Vey, Norbert ; Blaise, Didier. / A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. In: American Journal of Hematology. 2014 ; Vol. 89, No. 1. pp. 83-87.
@article{5b194563d93343a186b88e2bb17dc5ac,
title = "A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor",
abstract = "Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N=74) or MMUD (N=40). We compared outcome of MUD versus MMUD patients. There was no difference in the cumulative incidence of grades II-IV acute GVHD (MUD: 34{\%} vs. MMUD: 35{\%}, P=0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5{\%} vs. MMUD: 15{\%}, P=0.016). The cumulative incidences of overall chronic GVHD (MUD: 33{\%} vs. MMUD: 22{\%}, P=0.088) and extensive chronic GVHD (MUD: 20{\%} vs. MMUD: 19{\%}, P=0.594) were comparable. One-year NRM was similar in both groups (MUD: 16{\%} vs. MMUD: 14{\%}, P=0.292); similarly, progression-free survival (MUD: 59{\%} vs. MMUD: 55{\%}, P=0.476) and overall survival (MUD: 63{\%} vs. MMUD: 61{\%}, P=0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47{\%}) and 19 of 40 MMUD patients (48{\%}) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients.",
author = "Raynier Devillier and Sabine F{\"u}rst and Roberto Crocchiolo and Jean El-Cheikh and Luca Castagna and Samia Harbi and Angela Granata and Evelyne D'Incan and Diane Coso and Christian Chabannon and Christophe Picard and Anne Etienne and Boris Calmels and Schiano, {Jean Marc} and Claude Lemarie and Stoppa, {Anne Marie} and Reda Bouabdallah and Norbert Vey and Didier Blaise",
year = "2014",
month = "1",
doi = "10.1002/ajh.23592",
language = "English",
volume = "89",
pages = "83--87",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor

AU - Devillier, Raynier

AU - Fürst, Sabine

AU - Crocchiolo, Roberto

AU - El-Cheikh, Jean

AU - Castagna, Luca

AU - Harbi, Samia

AU - Granata, Angela

AU - D'Incan, Evelyne

AU - Coso, Diane

AU - Chabannon, Christian

AU - Picard, Christophe

AU - Etienne, Anne

AU - Calmels, Boris

AU - Schiano, Jean Marc

AU - Lemarie, Claude

AU - Stoppa, Anne Marie

AU - Bouabdallah, Reda

AU - Vey, Norbert

AU - Blaise, Didier

PY - 2014/1

Y1 - 2014/1

N2 - Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N=74) or MMUD (N=40). We compared outcome of MUD versus MMUD patients. There was no difference in the cumulative incidence of grades II-IV acute GVHD (MUD: 34% vs. MMUD: 35%, P=0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5% vs. MMUD: 15%, P=0.016). The cumulative incidences of overall chronic GVHD (MUD: 33% vs. MMUD: 22%, P=0.088) and extensive chronic GVHD (MUD: 20% vs. MMUD: 19%, P=0.594) were comparable. One-year NRM was similar in both groups (MUD: 16% vs. MMUD: 14%, P=0.292); similarly, progression-free survival (MUD: 59% vs. MMUD: 55%, P=0.476) and overall survival (MUD: 63% vs. MMUD: 61%, P=0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47%) and 19 of 40 MMUD patients (48%) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients.

AB - Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N=74) or MMUD (N=40). We compared outcome of MUD versus MMUD patients. There was no difference in the cumulative incidence of grades II-IV acute GVHD (MUD: 34% vs. MMUD: 35%, P=0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5% vs. MMUD: 15%, P=0.016). The cumulative incidences of overall chronic GVHD (MUD: 33% vs. MMUD: 22%, P=0.088) and extensive chronic GVHD (MUD: 20% vs. MMUD: 19%, P=0.594) were comparable. One-year NRM was similar in both groups (MUD: 16% vs. MMUD: 14%, P=0.292); similarly, progression-free survival (MUD: 59% vs. MMUD: 55%, P=0.476) and overall survival (MUD: 63% vs. MMUD: 61%, P=0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47%) and 19 of 40 MMUD patients (48%) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients.

UR - http://www.scopus.com/inward/record.url?scp=84892848639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892848639&partnerID=8YFLogxK

U2 - 10.1002/ajh.23592

DO - 10.1002/ajh.23592

M3 - Article

C2 - 24108528

AN - SCOPUS:84892848639

VL - 89

SP - 83

EP - 87

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -